MabiobCD20 is a monoclonal antibody used to treat blood cancer, lymphomas and leukemias.
The clinical program will involve 600-700 patients and will last approximately two years.
Mabion president Maciej Wieczorek said after completion of clinical trials they will prepare the necessary documentation and will apply for registration in the EU Member States.
"In parallel, we will try to register the drug in countries such as Russia, China and Turkey," Wieczorek said.
"We will need money in order to implement the first two drugs, namely MabionCD20 and MabionHER2 and to build a new manufacturing plant."
Mabion also plans to start clinical trial of MabionHER2, a monoclonal antibody to treat breast cancer.